TABLE 2.
Characteristics of the Covid-19 patients (n = 50)
| Demographics | Covid-19 patients |
|---|---|
| Age (years) | 69 ± 10 |
| Hospitalisation period (days) | 15 ± 9 |
| Female gender (%) | 19 (38%) |
| Smoker (Current or Former) (%) | 4 (8%) |
| Comorbidities | |
| Diabetes (%) | 16 (32%) |
| Ischemic heart disease (%) | 9 (18%) |
| Cerebrovascular disease (%) | 11 (22%) |
| Hypertension (%) | 35 (70%) |
| Dislipidemia (%) | 19 (38%) |
| Obesity (%) | 9 (18%) |
| Cancer (%) | 2 (4%) |
| Chronic Obstructive Pulmonary Disease (%) | 4 (8%) |
| Previous medication | |
| Medications for hypertension (%) | 25 (50%) |
| Aspirin (%) | 14 (28%) |
| Statin (%) | 19 (38%) |
| In-hospital treatment | |
| Steroid (%) | 42 (84%) |
| Remdesivir (%) | 17 (34%) |
| Antibiotics (%) | 26 (52%) |
| Respiratory status | |
| Mechanical ventilation (%) | 17 (34%) |
| High flow oxygen (%) | 9 (18%) |
| Low flow oxygen (%) | 19 (38%) |
| Room air (%) | 5 (10%) |
| P/F | 200.5 ± 99.3 |
| Venous thromboembolism (%) | 3 (6%) |
| Chest X ray | |
| Normal (%) | 10 (20%) |
| Intersrtitial signs (%) | 10 (20%) |
| Consolidations (%) | 30 (60%) |
| Clinical Outcome | |
| Hospitalization period (days) for discharged patients | 16 ± 9 |
| Death (%) | 6 (12%) |
| Main Laboratory findings | |
| Hemoglobin, g/dL | 12.8 ± 2.1 |
| White blood cell count, × 109/L | 9.0 ± 3.8 |
| C-reactive protein, mg/L | 101.4 ± 81.2 |
| Procalcitonin, ng/mL | 0.7 ± 1.5 |
| Total cholesterol, mg/dL | 162.8 ± 34.9 |
| LDL cholesterol, mg/dL | 97.1 ± 35.2 |
| HDL cholesterol, mg/dL | 41.4 ± 10.2 |
| Triglycerides, mg/dL | 122.7 ± 66.4 |
| FRS Median value (IQR) | 28.95 (17.48 - 30.00) |
| ASCVD Plus Median value (IQR) | 15.50 (6.97 – 37.65) |
ASCVD, atherosclerotic cardiovascular disease; FRS, Framingham Risk Score 2008; HDL, high-density lipoproteins; LDL, low-density lipoproteins; P/F: PaO2/FiO2 ratio, the calculated ratio of arterial oxygen partial pressure to fractional inspired oxygen. Data are expressed as n (%) or mean ± standard deviation (SD).